Medtronic Insulin Pump Air Pressure Issues Could Lead to Dangerously Low Blood Sugar Levels

Medtronic MiniMed Insulin Pump Air Pressure Issues Could Lead to Dangerously Low Blood Sugar Levels FDA

Federal health officials have issued a recall for 41,404 Medtronic MiniMed insulin pumps after discovering a risk of delivering incorrect insulin doses due to air pressure fluctuations, such as those experienced during airplane takeoff and landing.

Medtronic MiniMed insulin pumps are medical devices used by people with diabetes to help manage blood sugar levels. They deliver a continuous supply of insulin throughout the day and additional doses as needed.

However, the U.S. Food and Drug Administration (FDA) announced the Medtronic MiniMed insulin pump recall on March 3, warning that the device may deliver incorrect insulin doses in response to air pressure fluctuations. These changes can occur during airplane flights, high-altitude hikes, rapid elevator rides in skyscrapers, or travel through mountainous regions.

Unexpected over-delivery of insulin during these moments could result in severe hypoglycemia, leading to altered mental states, seizures, coma or death. In addition, unexpected under-delivery could cause severe hyperglycemia, dehydration, diabetic ketoacidosis or death.

Ultra-Processed-Foods-Lawsuit-Lawyer
Ultra-Processed-Foods-Lawsuit-Lawyer

Medtronic first issued an urgent medical device correction notice on January 31, advising customers to monitor their glucose levels, discuss with their doctors any strategies for managing changes in air pressure, and respond promptly to alerts and symptoms.

The recalled Medtronic MiniMed insulin pumps were distributed globally, and across all U.S. states and territories. The recall applies to Paradigm, MiniMed 530G, 6XX and 7XX series pumps, covering all lot numbers and Unique Device Identifier (UDI) numbers.

Customers with questions can contact Medtronic Technical Support at 1-800-646-4633, ext. 1 for further assistance.

Medtronic MiniMed Lawsuits

The Medtronic MiniMed has been at the center of multiple recalls in recent years due to serious defects, leading to a wave of MiniMed lawsuits filed by patients who suffered severe injuries or lost loved ones. These recalls have involved malfunctions that caused insulin overdoses, cybersecurity vulnerabilities and dangerous dosing errors, raising significant concerns about the safety of Medtronic’s insulin pump technology.

In August 2023, a MiniMed wrongful death lawsuit was filed against Medtronic after a man fatally overdosed on insulin when his MiniMed pump malfunctioned. 

According to the lawsuit, Michael E. Domanowski properly loaded his insulin pump before going to bed on August 9, 2020, but was later found dead on his floor after failing to show up for work for several days. Investigators determined that the pump had delivered up to a week’s worth of insulin in a single dose, causing severe hypoglycemia that led to his painful and prolonged death. A post-mortem examination confirmed dangerously low blood sugar levels throughout his body.

The MiniMed pump used by Domanowski was later recalled due to the risk of malfunction and overdose, the lawsuit notes. Medtronic employees contacted the family within a few days of his death to alert Domanowski to the recall. However, the lawsuit says it was an attempt “to cover their own misconduct.”

In September 2022, the FDA issued a warning about potentially deadly cybersecurity vulnerabilities in certain MiniMed insulin pumps. The FDA warned that the pump systems wireless communication software could be accessed by a nearby unauthorized user while the pump is paired with other system components like continuous glucose monitoring systems, blood glucose meters and CareLink USB devices.

Dosing problems were also mentioned in a February 2020 MiniMed insulin pump recall, which preceded numerous lawsuits, including one from a South Carolina woman filed in March of that year, alleging that her Medtronic infusion pump malfunctioned. As a result, she was overdosed with insulin, fell into a diabetic coma, suffered seizures, and sustained other injuries.


0 Comments


Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

MORE TOP STORIES

A group of eight lawyers have been recommended to serve in various leadership positions in the Biozorb litigation, taking actions that benefit all plaintiffs pursuing cases over injuries caused by the recalled breast tissue marker.